Information about Actos and bladder cancer.
Welcome

Actos Warnings

In June 2011, the Food and Drug Administration issued a warning in that the use of the diabetes drug Actos may increase a patient’s risk of developing bladder cancer. The agency also warned of a bladder cancer risk from the use of the drugs Actoplus Met, Actoplus Met XR and Duetact, which contain the same active chemical (pioglitazone) as Actos.

The FDA’s Actos warning was based on preliminary results of a 10-year study examining the drug’s link with bladder cancer. The study found that patients who were treated with Actos for more than one year or who were prescribed the highest doses of the drug were at a higher risk of developing bladder cancer.

In a warning letter issued to physicians, the FDA stated that doctors should not prescribe Actos to patients who currently have bladder cancer. The agency also advised doctors to use caution when prescribing the drug to patients who were previously treated for the disease, and to weigh the drug’s potential benefits as a diabetes treatment against the risks of cancer recurrence.

The FDA’s Actos bladder cancer warning also advised patients to talk with their doctor if they develop any symptoms of this disease, including blood or a red color in the urine, pain while urinating, an urgent need to go to the bathroom, lower back pain or abdominal pain.

In August 2007, the FDA issued a black-box warning concerning Actos after the drug was linked to an increased risk of heart failure. Other studies have also linked Actos to an increased risk of heart attack.

If you or a loved one were diagnosed with bladder cancer after using Actos—or developed any of the previously-mentioned symptoms of the disease—you may qualify to file a lawsuit. For a free legal consultation, contact the lawyers at Hissey Kientz, LLP by calling toll-free at 1-866-275-4454, or by filling out the free case evaluation form located on this page.

Contact Us Today for a Free Consultation.

YesNo
I am currently represented by an attorney.
captcha
*Required fields